Acadian Asset Management
CLSD

Acadian Asset Management’s Clearside Biomedical CLSD Stock Holding History

Acadian Asset Management’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,169
Closed -$15K – 1688
2023
Q3 		$15K Sell
1,169
-1,109
-49% -$16.8K ﹤0.01% 1571
2023
Q2 		$37K Sell
2,278
-6,870
-75% -$118K ﹤0.01% 1562
2023
Q1 		$141K Hold
9,148
– – ﹤0.01% 1329
2022
Q4 		$152K Buy
9,148
+7,028
+332% +$127K ﹤0.01% 1348
2022
Q3 		$35K Sell
2,120
-236
-10% -$5.17K ﹤0.01% 1540
2022
Q2 		$51K Buy
+2,356
New +$57.2K ﹤0.01% 1492

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Acadian Asset Management's CLSD Position: Q4 2023 in Review

Acadian Asset Management sold out of Clearside Biomedical (CLSD) in Q4 2023, closing a stake of 1,169 shares — an estimated $15K sold.

Acadian Asset Management first reported a position in CLSD in Q2 2022 and held it in 6 quarters. The position peaked at $152K in Q4 2022. 46 funds tracked by Wall St. Rank hold CLSD as of Q4 2023.

  • Acadian Asset Management reported no remaining Clearside Biomedical position as of Q4 2023 after selling out during the quarter.
  • Acadian Asset Management sold 1,169 Clearside Biomedical shares in Q4 2023, an estimated $15K.
  • Acadian Asset Management first reported a position in Clearside Biomedical in Q2 2022 and held it in 6 quarters.
  • Acadian Asset Management's Clearside Biomedical position peaked at $152K in Q4 2022.
  • 46 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2023.

Based on Acadian Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.